Asha Therapeutics (Asha), a neuro-centric biotechnology firm specializing in creating novel therapeutics for neurological ailments with excessive unmet medical want utilizing its disruptive PRISM™ expertise, at this time introduced the appointment of Kirsten Flowers to its Board of Administrators.
Asha’s PRISM™ expertise has resulted in a pipeline of belongings that treats neurological illness by contemplating neuronal deterioration and loss from a number of vantage factors. Inside Asha’s pipeline, lead asset ASHA-091 is a first-in-class, close to clinic-ready custom-designed mind penetrant compound that restores the mitochondrial community, selling cell survival over cell loss of life in quite a lot of neurological circumstances.
Sam Shrivastava, Asha’s Founder and CEO, famous, “Kirsten Flowers is a seasoned government whose in depth expertise inside pharma and biotech might be tremendously additive to Asha as we progress our sturdy pipeline of belongings in the direction of clinic. Her confirmed strategic and operational experience from early stage drug growth via commercialization and acquisition will present precious experience as Asha continues to advance our portfolio.”
Ms. Flowers mentioned, “I’ve been impressed by Asha’s means to effectively develop a number of, revolutionary belongings and see vital potential of their proprietary PRISM™ platform. I’m honored to affix the Board of Administrators and sit up for collaborating with Asha’s proficient workforce and Board as they advance their first-in-class portfolio into the clinic with the purpose of addressing a number of neurological ailments of excessive unmet want.”
Ms. Flowers most just lately served because the Chief Business & Company Technique officer for Kura Oncology and brings greater than 20 years of pharmaceutical and biotech expertise in creating revolutionary product and pipeline methods to extend enterprise worth, main profitable product launches, managing P&Ls, and serving to to recruit, construct, and encourage government groups in each giant pharma and smaller biotech organizations. Previous to Kura Oncology, Kirsten served because the Sr. Vice-President of Business Operations at Array Biopharma, the place she constructed and led the business group that delivered the profitable launch of Braftovi® + Mektovi® in the end leading to an $11.4 billion firm acquisition by Pfizer. Earlier than becoming a member of Array, she held a number of ascending management positions inside Pfizer together with the U.S. business lead for the launch of the blockbuster medicine IBRANCE® in breast most cancers and INLYTA® in renal cell carcinoma. Kirsten additionally serves on the Board of Administrators of Comera Life Sciences (Nasdaq: CMRA) and PMV Prescribed drugs, Inc. (Nasdaq: PMVP). Kirsten earned her MBA from Harvard Enterprise Faculty, and her BS in Molecular & Mobile Biology and Psychology from the College of Arizona.